Who can use Xagrid(bictegravir/emtricitabine/tenofovir alafenamide)?

BIKTARVY is indicated as a complete regimen for HIV-1 infection in adults and children weighing at least 14 kg under specific conditions.

Approved Uses

BIKTARVY is approved for treating human immunodeficiency virus type 1 (HIV-1) infection in patients with no prior antiretroviral treatment history, those with a treatment history who are not virologically suppressed but have no known resistance to its components, or as a replacement for current regimens in virologically suppressed individuals. Virologic suppression is defined as HIV-1 RNA less than 50 copies per mL. It is essential that patients have no substitutions associated with resistance to bictegravir, emtricitabine, or tenofovir. This broad indication ensures flexibility in clinical use across different stages of HIV management.